This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Psychiatry, Other  • Alert me on articles by topic

Arch Gen Psychiatry. 1999;56:355.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE ARTICLE by Bunney et al¹ is a partial report of the efficacy and safety of triazolam (Halcion; Upjohn Co, Kalamazoo, Mich) for use as a sedative and hypnotic medication. The report was requested by the Food and Drug Administration (FDA) task force to provide an independent assessment of the safety and efficacy of this compound. The 7 recommendations of this report suggest the need for more data, better integration of clinical trial and postmarketing surveillance data, increased attention to long-term clinical trials, and development of methods to assess long-term effects, in terms of efficacy, tolerance, and safety.

In clinical practice, sedative and hypnotic medications are frequently prescribed for much longer periods than those in which they have been studied in premarketing clinical trials. Thus, the clinical use of sedative and hypnotic medications is often longer than that reported in the database regarding safety that is provided to the FDA. . . . [Full Text of this Article]